secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001628280-23-037916
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Q3 2023: Total revenue $55M (-17% YoY); Cell Engineering up 51%; revises FY23 outlook
--------------------------------------------------------------------------------

- Cell Engineering revenue $37M (+51% YoY); Biosecurity revenue $18M with 62% gross margin.
- Loss from ops $(286)M including $96M impairment charge; Adj. EBITDA $(84)M vs $(72)M prior year.
- Added 21 new Cell Programs in Q3, 40% growth YoY; full-year target revised to 80-85 programs.
- New partnerships: Pfizer RNA drug discovery (up to $331M milestones) and Google Cloud AI deal.
- FY23 revenue guidance cut to $250-260M; Cell Engineering $145-150M; Biosecurity up to $110M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000162828023037916/0001628280-23-037916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000162828023037916/dna-20231108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-037916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer